文献速递头痛与眩晕

Erenumab治疗发作性偏头痛:开放标签研究中期分析

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
PubMed 文献 · Neurology · 2017-08-23

本项开放标签扩展研究中期分析评估了Erenumab 70mg每4周一次皮下注射在发作性偏头痛患者中的长期安全性和有效性。383例患者接受治疗,中位暴露575天,第64周时月偏头痛天数平均较基线减少5.0天,65%患者达到≥50%缓解,安全性与双盲阶段相似。

要点

  • Erenumab 70mg每4周一次在发作性偏头痛患者中显示持续1年的疗效。
  • 第64周时65%患者月偏头痛天数减少≥50%,42%减少≥75%,26%完全缓解。
  • 长期安全性与双盲阶段及安慰剂相似,支持进一步研究。

核心结论

  • Erenumab 70mg每4周一次在发作性偏头痛患者中治疗1年,可减少月偏头痛天数并改善头痛相关残疾和偏头痛特异性生活质量,安全性和耐受性良好。

研究设计与样本

  • 发作性偏头痛患者完成12周双盲安慰剂对照试验后进入开放标签扩展研究,接受Erenumab 70mg每4周一次治疗至多5年。
  • 本次预设中期分析在所有参与者完成1年开放标签随访后进行,报告观察数据,未对缺失数据进行插补。

主要发现

  • 472例患者入组母研究,383例继续进入开放标签扩展,中位暴露575天(范围28-822天)。
  • 月偏头痛天数均值(SD)在母研究基线为8.8(2.6)天,第12周(开放标签开始)为6.3(4.2)天,第64周为3.7(4.0)天,较基线平均减少5.0天。
  • 第64周时,65%、42%和26%的患者分别达到月偏头痛天数减少≥50%、≥75%和100%。
  • HIT-6评分均值(SD)在基线为60.2(6.3),第64周为51.7(9.2);MSQ和MIDAS改善维持至第64周。
  • 开放标签期间安全性特征与双盲阶段相似,总体与安慰剂相似。

临床怎么用

  • 对于发作性偏头痛患者,Erenumab 70mg每4周一次可作为预防性治疗选择,长期使用可减少偏头痛天数并改善生活质量。
  • 治疗期间应关注月偏头痛天数变化及HIT-6、MSQ、MIDAS等评估指标,以监测疗效。

局限性

  • 本研究为开放标签扩展研究,无对照组,证据等级为Class IV。
  • 数据报告为观察数据,未对缺失数据进行插补。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (EM). METHODS: Patients enrolled in a 12-week, double-blind, placebo-controlled clinical trial (NCT01952574) who continued in an open-label extension (OLE) study will receive erenumab 70 mg every 4 weeks for up to 5 years. This preplanned interim analysis, conducted after all participants had completed the 1-year open-label follow-up, evaluated changes in monthly migraine days (MMD), achievement of ≥50%, ≥75%, and 100% reductions, Headache Impact Test (HIT-6) score, Migraine-Specific Quality of Life (MSQ), Migraine Disability Assessment (MIDAS), and safety. Data reported as observed without imputation for missing data. RESULTS: Of 472 patients enrolled in the parent study, 383 continued in the OLE with a median exposure to erenumab of 575 days (range 28-822 days). Mean (SD) MMD were 8.8 (2.6) at parent study baseline, 6.3 (4.2) at week 12 (beginning of OLE), and 3.7 (4.0) at week 64 (mean change from baseline [reduction] of 5.0 days). At week 64, 65%, 42%, and 26% achieved ≥50%, ≥75%, and 100% reduction in MMD, respectively. Mean HIT-6 scores were 60.2 (6.3) at baseline and 51.7 (9.2) at week 64. MSQ and MIDAS improvements from baseline were maintained through week 64. Safety profiles during the OLE were similar to those in the double-blind phase, which overall were similar to placebo. CONCLUSIONS: One-year efficacy, supported by functional improvements and favorable safety and tolerability profiles, supports further investigation of erenumab as a preventive treatment in patients with EM. CLINICALTRIALSGOV IDENTIFIER: NCT01952574. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with episodic migraine, erenumab reduces long-term MMD and improves headache-related disability and migraine-specific quality of life.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017. PMID: 28835404. doi:10.1212/WNL.0000000000004391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。